Frequently Asked Question
Third party pharma manufacturing is a business model where a company outsources the production of its pharmaceutical products to a certified manufacturer.
A company provides product requirements and the manufacturer handles production, packaging and quality compliance under agreed terms.
It reduces investment costs, saves time, ensures quality production and allows companies to focus on marketing and distribution.
Yes, it is legal and regulated by authorities like WHO, GMP and DCGI, ensuring quality and safety standards.
Key documents include a drug license, GST registration, agreement copy, and product permission from regulatory authorities.
PCD franchise focuses on distribution rights, while third party manufacturing focuses on product production by a manufacturer.
Look for certifications, experience, product range, quality standards, pricing and timely delivery.
Important certifications include WHO-GMP, ISO, and DCGI approvals.
Yes, it is ideal for startups and small businesses due to low investment and scalability.
Products include tablets, capsules, syrups, injectables, ointments and nutraceuticals.
Costs vary depending on product type, quantity, packaging and formulation requirements.
Production timelines typically range from 30 to 60 days, depending on order size and product type.
It is a legal contract between the company and manufacturer outlining production terms, pricing and responsibilities.
Yes, most manufacturers offer complete packaging and labeling solutions.
Yes, reputed manufacturers follow strict quality control processes and regulatory guidelines.
Yes, companies can customize formulations, packaging design and branding.
MOQ stands for Minimum Order Quantity, which varies depending on the manufacturer and product.
No, monopoly rights are generally offered in PCD pharma franchise models, not in manufacturing services.
Risks include poor quality from unreliable manufacturers, delays and regulatory issues if compliance is not met.
It is cost-effective, scalable and supported by a strong pharmaceutical manufacturing infrastructure.
